Screener / SEC EDGAR /CIK 0001295947 /10-K filed May 14, 2026, compared with May 9, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Prestige Consumer Healthcare Inc. PBH

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What PBH's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 5, 2026, PBH reported $1.14 per share under GAAP and $2.11 on its own adjusted basis: the adjusted number is +85% above GAAP.

GAAP EPS $0.98, release May 14, 2024: Diluted earnings per share of $0.98 for the fourth quarter of fiscal 2024 compared to a $4.83 diluted loss per share in the prior year comparable period. Adjusted EPS $1.02, release May 14, 2024: Non- GAAP adjusted diluted earnings per share of $1.02 per share for the fourth quarter of fiscal 2024 compared to $1.07 per share in the prior year comparable period. +4% 2024-05 GAAP EPS $0.98, release Aug 8, 2024: 30, 2024 2023 Net Income Diluted EPS Net Income Diluted EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS 49,068$ 0.98$ 53,276$ 1.06$ Adjustments: Normalized Adjusted EPS $0.90, release Aug 8, 2024: tax rate adjustment(a) (4,030) (0.08) - - Total Adjustments (4,030) (0.08) - - Non-GAAP Adjusted Net Income and Adjusted Diluted EPS 45,038$ 0.90$ 53,276$ 1.06$ (a) Income tax adjustmen -8% 2024-08 GAAP EPS $1.09, release Nov 7, 2024: Diluted EPS Net Income Diluted EPS Net Income Diluted EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS 54,377$ 1.09$ 53,559$ 1.07$ 103,445$ 2.06$ 106,835$ Adjusted EPS $1.09, release Nov 7, 2024: - - - - (4,030) (0.08) - - Total Adjustments - - - - (4,030) (0.08) - - Non-GAAP Adjusted Net Income and Adjusted Diluted EPS 54,377$ 1.09$ 53,559$ 1.07$ 99,415$ 1.98$ 106,835$ 2 +0% 2024-11 GAAP EPS $1.00, release May 8, 2025: Diluted earnings per share of $1.00 for the fourth quarter of fiscal 2025 compared to $0.98 in the prior year comparable period. Adjusted EPS $1.32, release May 8, 2025: Non-GAAP adjusted diluted earnings per share of $1.32 per share for the fourth quarter of fiscal 2025 compared to $1.02 per share in the prior year comparable period. +32% 2025-05 GAAP EPS $0.95, release Aug 7, 2025: 30, 2025 2024 Net Income Diluted EPS Net Income Diluted EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS 47,466$ 0.95$ 49,068$ 0.98$ Adjustments: Normalized Adjusted EPS $0.95, release Aug 7, 2025: tax rate adjustment (a) - - (4,030) (0.08) Total Adjustments - - (4,030) (0.08) Non-GAAP Adjusted Net Income and Adjusted Diluted EPS 47,466$ 0.95$ 45,038$ 0.90$ Three Months Ended June +0% 2025-08 GAAP EPS $0.86, release Nov 6, 2025: Diluted earnings per share of $0.86 and non-GAAP adjusted diluted earnings per share of $1.07 for the second quarter of fiscal 2026 compared to $1.09 diluted earnings per share in the prior year comparable period. Adjusted EPS $1.07, release Nov 6, 2025: Diluted earnings per share of $0.86 and non-GAAP adjusted diluted earnings per share of $1.07 for the second quarter of fiscal 2026 compared to $1.09 diluted earnings per share in the prior year comparable period. +24% 2025-11 GAAP EPS $0.97, release Feb 5, 2026: Diluted earnings per share of $0.97 and non-GAAP adjusted diluted earnings per share of $1.14 for the third quarter of fiscal 2026 compared to diluted earnings per share of $1.22 in the prior year comparable period. Adjusted EPS $1.14, release Feb 5, 2026: Diluted earnings per share of $0.97 and non-GAAP adjusted diluted earnings per share of $1.14 for the third quarter of fiscal 2026 compared to diluted earnings per share of $1.22 in the prior year comparable period. +18% 2026-02 GAAP EPS $1.13, release May 13, 2026: Diluted earnings per share of $1.13 for the fourth quarter of fiscal 2026 compared to $1.00 in the prior year comparable period. Adjusted EPS $1.23, release May 13, 2026: Non-GAAP adjusted diluted earnings per share of $1.23 for the fourth quarter of fiscal 2026 compared to $1.32 in the prior year comparable period. +9% 2026-05 GAAP EPS $1.14, release Nov 5, 2026: Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. Adjusted EPS $2.11, release Nov 5, 2026: Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02. +85% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. release
Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02. release

What the company says its adjusted numbers leave out:

F I R S T Q U A R T E R F Y 2 6 R E S U L T S 16 Reconciliation Schedules (Continued) Adjusted Diluted EPS Free Cash Flow (a) Income tax adjustment to adjust for discrete income tax items. release Aug 7, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

Open on SEC

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

• Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07

• The Breathe Right ® portfolio and LaCorium acquisitions performed as expected in first full quarter of ownership

• Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48 to $4.55 in Adjusted Diluted EPS

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.

“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right ® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Reported revenues in the second quarter of fiscal 2027 of $336.3 million increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but decreased 1.6% excluding the impacts of foreign currency and a $65.1 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue performance versus the prior year comparable period reflected the expected headwind associated with order timing in Q1 and a decline in Clear Eyes®.

Reported net income for the second quarter of fiscal 2027 totaled $25.3 million, or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in diluted earnings per share, for the comparable period of fiscal 2026. On an adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8 million, or $1.13 in diluted earnings per share, versus $52.5 million in net income and $1.07 in diluted earnings per share in the prior year comparable period.

Adjustments to net income in the second quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long- term capacity, a loss on extinguishment of debt, associated tax adjustments and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the second quarter of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

Reported revenues for the first six months of fiscal 2027 totaled $602.0 million and compared to revenues of $523.6 million for the first six months of fiscal 2026. Revenues increased 15.0% versus the prior year comparable period and 0.7% excluding the impact of foreign currency and a $71.0 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue

increase for the first six months reflected increased demand across the broad portfolio which more than offset a decline in Clear Eyes®.

Reported net income for the first six months of fiscal 2027 totaled $54.5 million versus the prior year comparable period net income of $89.7 million. Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled $100.3 million versus the prior year comparable period’s adjusted net income of $99.9 million. Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02.

Adjustments to net income in the first six months of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, as well as a loss on extinguishment of debt, associated tax adjustments, and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the first six months of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

The Company's net cash provided by operating activities for the first six months of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first six months of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year comparable period.

The Company's net debt position as of September 30, 2026 was approximately $2 billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior notes due July 2034, which replaced the same principal of senior notes previously due in fiscal 2028.

North American OTC Healthcare : Segment revenues of $271.8 million for the second quarter fiscal 2027 increased 17.8% compared to the prior year comparable quarter's segment revenues of $230.8 million. The revenue increase was driven by a $47.5 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, partially offset by lower base business sales associated with accelerated order timing in first quarter fiscal 2027.

For the first six months of the current fiscal year, reported revenues for the North American OTC segment were $498.0 million, which compared to $443.3 million in the prior year comparable period.

The revenue increase was primarily driven by a $52.0 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as higher CompoundW ® and TheraTears ® sales.

International OTC Healthcare : Fiscal second quarter 2027 segment revenues of $64.5 million increased 48.7% compared to $43.4 million reported in the prior year comparable period. The revenue performance was primarily driven by a $17.6 million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as double-digit sales growth for Hydralyte ® .

For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $104.0 million, an increase of approximately 30% over the prior year comparable period’s revenues of $80.3 million. Strong revenue growth was primarily driven by a $19.0

million contribution from the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as continued growth for Hydralyte ®.

Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half. While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site with the intent of delivering consistent quality output that generates long-term growth for the brand."

"It's important to note that our outlook for the remainder of the portfolio is unchanged, with the base business delivering growth and our recent acquisitions on track to deliver sales and profit consistent with our prior guidance. Against a challenging consumer environment, this is a testament to our trusted brands and diversified business model."

“We remain confident in our business, the strategic investments we have made over the past twelve months, and our medium-term outlook for approximately 10% annual revenue growth, approximately 8% annual EPS growth, and nearly $900 million of aggregate free cash flow over the next three years. The acquisitions of Breathe Right® and LaCorium provide attractive long-term growth opportunities as we integrate these brands into our portfolio. The acquisition of Pillar5 will provide vertical integration of our eye care supply chain and an important platform for continued investment in capacity, reliability and long-term growth. Together, these investments further strengthen our diversified portfolio and financial profile while supporting strong free cash flow, debt reduction and future capital deployment,” Mr. Lombardi concluded.

Previous Fiscal 2027 Current Fiscal 2027 Outlook Outlook Revenue $1,290 to $1,315 $1,280 to $1,290 million million Organic Revenue Growth +1.0% to +3.0% ~ Flat Adjusted Diluted $4.55 to $4.65 $4.48 to $4.55 E.P.S. Adjusted Free Cash $270 million or more $265 million or more Flow

Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its second quarter and first half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and adjusted free cash flow; supply of Clear Eyes® and return to category leadership; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s sales and profit; the Company’s ability to rapidly reduce debt; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives and ordering patterns, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.

September 30, (In thousands) 2026 March 31, 2026 ────────────────────────────────────────────────────────────────────────────── Assets Current assets Cash and cash $ 46,515 $ 63,868 equivalents Accounts receivable, net of allowance of 244,124 191,920 $24,135 and $18,187, respectively Inventories 179,203 159,132 Prepaid expenses and other current 22,286 16,564 assets Total current 492,128 431,484 assets Property, plant and equipment, 116,868 121,689 net Operating lease right-of-use 24,621 27,780 assets Finance lease right-of-use 20,136 21,776 assets, net Goodwill 705,264 581,109 Intangible 3,357,059 2,299,605 assets, net Other long-term 5,585 10,870 assets Total Assets $ 4,721,661 $ 3,494,313 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 44,020 $ 22,791 Accrued interest 16,528 15,578 payable Operating lease liabilities, 7,218 6,910 current portion Finance lease liabilities, 2,743 2,656 current portion Other accrued 97,994 72,989 liabilities Total current 168,503 120,924 liabilities Long-term debt, 2,079,324 993,953 net Deferred income 489,533 447,417 tax liabilities Long-term operating lease liabilities, 17,509 20,955 net of current portion Long-term finance lease liabilities, net 16,576 17,968 of current portion Other long-term 5,551 5,580 liabilities Total Liabilities 2,776,996 1,606,797 Total Stockholders' 1,944,665 1,887,516 Equity Total Liabilities and Stockholders' $ 4,721,661 $ 3,494,313 Equity

Six Months Ended (In thousands) September 30, Operating Activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 54,472 $ 89,677 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 20,717 15,329 amortization Loss on disposal of property and 333 131 equipment Deferred and other 15,460 23,211 income taxes Amortization of debt 2,109 889 origination costs Amortization of acquired inventory 17,207 — step-up Stock-based 5,225 5,449 compensation costs Loss on extinguishment of 1,360 — debt Non-cash operating 4,192 3,879 lease cost Changes in operating assets and liabilities, net of the effects of acquisitions:

Accounts receivable -45,392 -2,580 Inventories 3,566 -10,277 Prepaid expenses and other current -6,181 -11,767 assets Accounts payable 16,023 22,545 Accrued liabilities 24,003 3,923 Operating lease -4,185 -3,839 liabilities Other -256 -71 Net cash provided by operating 108,653 136,499 activities Investing Activities Purchases of property, plant and -7,327 -2,940 equipment Acquisitions, net of -1,193,557 — cash acquired Other -1,757 -1,927 Net cash (used in) -1,202,641 -4,867 investing activities Financing Activities Proceeds from 1,140,000 — issuance of Term Loan Net increase in line 887 — of credit Term loan repayments -30,000 — Proceeds from issuance of senior 400,000 — notes Repayment of senior -400,000 — notes Payments of debt -28,829 — issuance costs Payments of finance -1,231 -1,147 leases Proceeds from exercise of stock 94 3,907 options Fair value of shares surrendered as -2,684 -4,216 payment of tax withholding Repurchase of common — -109,775 stock Other -1,486 — Net cash provided by (used in) financing 1,076,751 -111,231 activities Effects of exchange rate changes on cash -116 821 and cash equivalents (Decrease) increase in cash and cash -17,353 21,222 equivalents Cash and cash equivalents - 63,868 97,884 beginning of period Cash and cash equivalents - end of $ 46,515 $ 119,106 period Interest paid $ 41,124 $ 21,879 Income taxes paid $ 24,027 $ 25,088

*Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.

*Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment.

*Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.

* Intersegment revenues of $1.2 million were eliminated from the North American OTC Healthcare segment.

In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non- GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period- to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.

• Non-GAAP Organic Revenues : GAAP Total Revenues excluding revenues associated with acquisitions and the impact of foreign currency exchange rates in the periods presented.

• Non-GAAP Organic Revenue Change Percentage : Calculated as the change in Non- GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.

• Non-GAAP Adjusted Gross Margin : GAAP Gross Profit minus amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs.

• Non-GAAP Adjusted Gross Margin Percentage : Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.

• Non-GAAP Adjusted General and Administrative Expense : GAAP General and Administrative expenses minus costs associated with acquisitions.

• Non-GAAP Adjusted General and Administrative Expense Percentage : Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.

• Non-GAAP EBITDA : GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.

• Non-GAAP EBITDA Margin : Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.

• Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory fair value step‑up, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions, and loss on extinguishment of debt.

• Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.

• Non-GAAP Adjusted Net Income : GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions in General and Administrative Expense, loss on extinguishment of debt, applicable tax impact associated with these items and normalized tax rate adjustments.

• Non-GAAP Adjusted Diluted EPS : Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.

• Non-GAAP Free Cash Flow : Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.

• Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition and other costs paid.

• Net Debt : Calculated as total principal amount of debt outstanding ($2,110,000 at September 30, 2026) less cash and cash equivalents ($46,515 at September 30, 2026). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP. Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:

(a) Revenues associated with our Breathe Right® portfolio and LaCorium Health acquisitions are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments. Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:

(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels. Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:

(a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees. Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non- GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:

(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.

Note: Amounts may not add due to rounding. Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

: Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow

(In millions) ──────────────────────────────────────────────────────────── Projected FY'27 GAAP Net cash provided by $ 269 operating activities Additions to property and equipment for cash -26 Projected FY'27 Non-GAAP Free Cash Flow 243 Acquisition and other costs paid 22 Projected FY'27 Non-GAAP Adjusted Free Cash Flow $ 265

Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS (a):

Low High ────────────────────────────────────────────────────────────────────────────── Projected FY'27 GAAP Diluted EPS $ 3.53 $ 3.60 Adjustments: Costs associated with Pillar5 manufacturing optimization and 0.30 0.30 integration Costs associated with acquisitions of 0.64 0.64 the Breathe Right® portfolio and LaCorium Health Loss on extinguishment of debt 0.03 0.03 Tax impact of adjustments and normalized -0.02 -0.02 tax rate adjustments Total adjustments $ 0.95 $ 0.95 Projected FY'27 Non-GAAP Adjusted $ 4.48 $ 4.55 Diluted EPS

(a) The above reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 and Q2 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right® portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts.

Full text with the tables
                                                                    Exhibit 99.1
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

• Q2 Revenue of $336.3 million, up 22.7% versus prior year

• Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year
Adjusted Diluted EPS of $1.07

• The Breathe Right ® portfolio and LaCorium acquisitions performed as expected
in first full quarter of ownership

• Adjusting guidance outlook range to $1,280 to $1,290 million in revenue, $4.48
to $4.55 in Adjusted Diluted EPS

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026-- Prestige Consumer
Healthcare Inc. (NYSE:PBH) today reported financial results for its second
quarter and first half fiscal 2027 ended September 30, 2026.

“We were pleased with our second quarter and first half revenue and EPS
performance, driven by continued strength in our leading brands and strong early
contributions from the Breathe Right ® portfolio and LaCorium acquisitions that
closed in June and July, respectively. Our portfolio performed in line with our
expectations, with strong consumption growth across channels including
eCommerce. This translated into strong mid-single-digit earnings growth and sets
us up for continued strong free cash flow moving forward,” said Ron Lombardi,
Chief Executive Officer of Prestige Consumer Healthcare.
                                                                                
  Second Fiscal Quarter Ended September 30, 2026                                
                                                                                
Reported revenues in the second quarter of fiscal 2027 of $336.3 million
increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but
decreased 1.6% excluding the impacts of foreign currency and a $65.1 million
contribution from the acquisition of the Breathe Right® portfolio and LaCorium.
The organic revenue performance versus the prior year comparable period
reflected the expected headwind associated with order timing in Q1 and a decline
in Clear Eyes®.

Reported net income for the second quarter of fiscal 2027 totaled $25.3 million,
or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in
diluted earnings per share, for the comparable period of fiscal 2026. On an
adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8
million, or $1.13 in diluted earnings per share, versus $52.5 million in net
income and $1.07 in diluted earnings per share in the prior year comparable
period.

Adjustments to net income in the second quarter of fiscal 2027 included certain
costs associated with acquisitions including integration, transition, purchase
accounting, legal and various other costs, such as costs associated with
improving and optimizing the acquired Pillar5 facility for increases in long-
term capacity, a loss on extinguishment of debt, associated tax adjustments and
a normalized tax adjustment pertaining to the establishment of a valuation
allowance against deferred tax assets. The adjustment to the second quarter of
fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable
presence in a new state.
                                                                                
  Six Months Ended September 30, 2026                                           
                                                                                
Reported revenues for the first six months of fiscal 2027 totaled $602.0 million
and compared to revenues of $523.6 million for the first six months of fiscal
2026. Revenues increased 15.0% versus the prior year comparable period and 0.7%
excluding the impact of foreign currency and a $71.0 million contribution from
the acquisition of the Breathe Right® portfolio and LaCorium. The organic
revenue

increase for the first six months reflected increased demand across the broad
portfolio which more than offset a decline in Clear Eyes®.

Reported net income for the first six months of fiscal 2027 totaled $54.5
million versus the prior year comparable period net income of $89.7 million.
Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled
$100.3 million versus the prior year comparable period’s adjusted net income of
$99.9 million. Diluted earnings per share were $1.14 for the first six months of
fiscal 2027 compared to $1.81 per share in the prior year comparable period.
Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months
of fiscal 2027 increased over the prior year comparable period’s adjusted
diluted earnings per share of $2.02.

Adjustments to net income in the first six months of fiscal 2027 included
certain costs associated with acquisitions including integration, transition,
purchase accounting, legal and various other costs, such as costs associated
with improving and optimizing the acquired Pillar5 facility for increases in
long-term capacity, as well as a loss on extinguishment of debt, associated tax
adjustments, and a normalized tax adjustment pertaining to the establishment of
a valuation allowance against deferred tax assets. The adjustment to the first
six months of fiscal 2026 relates to a discrete tax item pertaining to
establishing a taxable presence in a new state.
                                                                                
  Free Cash Flow and Balance Sheet                                              
                                                                                
The Company's net cash provided by operating activities for the first six months
of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior
year comparable period. Non-GAAP adjusted free cash flow in the first six months
of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year
comparable period.

The Company's net debt position as of September 30, 2026 was approximately $2
billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior
notes due July 2034, which replaced the same principal of senior notes
previously due in fiscal 2028.
                                                                                
  Segment Review                                                                
                                                                                
North American OTC Healthcare : Segment revenues of $271.8 million for the
second quarter fiscal 2027 increased 17.8% compared to the prior year comparable
quarter's segment revenues of $230.8 million. The revenue increase was driven by
a $47.5 million contribution from the acquisitions of the Breathe Right ®
portfolio and LaCorium, partially offset by lower base business sales associated
with accelerated order timing in first quarter fiscal 2027.

For the first six months of the current fiscal year, reported revenues for the
North American OTC segment were $498.0 million, which compared to $443.3 million
in the prior year comparable period.

The revenue increase was primarily driven by a $52.0 million contribution from
the acquisitions of the Breathe Right ® portfolio and LaCorium, as well as
higher CompoundW ® and TheraTears ® sales.

International OTC Healthcare : Fiscal second quarter 2027 segment revenues of
$64.5 million increased 48.7% compared to $43.4 million reported in the prior
year comparable period. The revenue performance was primarily driven by a $17.6
million contribution from the acquisitions of the Breathe Right ® portfolio and
LaCorium, as well as double-digit sales growth for Hydralyte ® .

For the first six months of the current fiscal year, reported revenues for the
International OTC Healthcare segment were $104.0 million, an increase of
approximately 30% over the prior year comparable period’s revenues of $80.3
million. Strong revenue growth was primarily driven by a $19.0

million contribution from the acquisitions of the Breathe Right ® portfolio and
LaCorium, as well as continued growth for Hydralyte ®.
                                                                                
  Updated Fiscal 2027 Outlook                                                   
                                                                                
Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027
outlook for revenues to $1,280 million to $1,290 million and adjusted diluted
EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes®
production at Pillar5, which is expected to reduce product availability and
revenue in the second half. While supply remains limited for Clear Eyes®, we
continue to invest in our Pillar5 production site with the intent of delivering
consistent quality output that generates long-term growth for the brand."

"It's important to note that our outlook for the remainder of the portfolio is
unchanged, with the base business delivering growth and our recent acquisitions
on track to deliver sales and profit consistent with our prior guidance. Against
a challenging consumer environment, this is a testament to our trusted brands
and diversified business model."

“We remain confident in our business, the strategic investments we have made
over the past twelve months, and our medium-term outlook for approximately 10%
annual revenue growth, approximately 8% annual EPS growth, and nearly $900
million of aggregate free cash flow over the next three years. The acquisitions
of Breathe Right® and LaCorium provide attractive long-term growth opportunities
as we integrate these brands into our portfolio. The acquisition of Pillar5 will
provide vertical integration of our eye care supply chain and an important
platform for continued investment in capacity, reliability and long-term growth.
Together, these investments further strengthen our diversified portfolio and
financial profile while supporting strong free cash flow, debt reduction and
future capital deployment,” Mr. Lombardi concluded.
                                                                                
                            Previous Fiscal 2027       Current Fiscal 2027      
                            Outlook                    Outlook                  
  Revenue                   $1,290 to $1,315           $1,280 to $1,290         
                            million                    million                  
  Organic Revenue Growth    +1.0% to +3.0%             ~ Flat                   
  Adjusted Diluted          $4.55 to $4.65             $4.48 to $4.55           
  E.P.S.                                                                        
  Adjusted Free Cash        $270 million or more       $265 million or more     
  Flow                                                                          
                                                                                
Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and
Replay

The Company will host a conference call to review its second quarter and first
half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company
provides a live Internet webcast, a slide presentation to accompany the call, as
well as an archived replay, all of which can be accessed from the Investor
Relations page of the Company's website at
http://www.prestigeconsumerhealthcare.com. To participate in the conference call
via phone, participants may register for the call here to receive dial-in
details and a unique pin. While not required, it is recommended to join 10
minutes prior to the event start. The slide presentation can be accessed from
the Investor Relations page of the Company’s website by clicking on Webcasts and
Presentations.

A conference call replay will be available for approximately one week following
completion of the live call and can be accessed on the Company’s Investor
Relations page.
                                                                                
  Non-GAAP and Other Financial Information                                      
                                                                                
In addition to financial results reported in accordance with generally accepted
accounting principles (GAAP), we have provided certain non-GAAP financial
information in this release to aid investors in understanding the Company's
performance. Each non-GAAP financial measure is defined and reconciled to its
most closely related GAAP financial measure in the “About Non-GAAP Financial
Measures” section at the end of this earnings release.
                                                                                
  Note Regarding Forward-Looking Statements                                     
                                                                                
This news release contains "forward-looking statements" within the meaning of
the federal securities laws that are intended to qualify for the Safe Harbor
from liability established by the Private Securities Litigation Reform Act of
1995. "Forward-looking statements" generally can be identified by the use of
forward-looking terminology such as "guidance," "outlook," "may," "will,"
"would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,”
or "continue" (or the negative or other derivatives of each of these terms) or
similar terminology. The "forward-looking statements" include, without
limitation, statements regarding the Company's future operating results
including revenues, organic growth, adjusted diluted earnings per share, and
adjusted free cash flow; supply of Clear Eyes® and return to category
leadership; the expected impact of Breathe Right® and LaCorium Health
acquisitions on the Company’s sales and profit; the Company’s ability to rapidly
reduce debt; and the Company’s ability to manage through the current environment
through its business strategy and diverse product portfolio. These statements
are based on management's estimates and assumptions with respect to future
events and financial performance and are believed to be reasonable, though are
inherently uncertain and difficult to predict. Actual results could differ
materially from those expected as a result of a variety of factors, including
the impact of business and economic conditions, including as a result of
evolving U.S. and international tariffs, labor shortages, inflation and
geopolitical instability, consumer trends, the impact of the Company’s
advertising and marketing and new product development initiatives, customer
inventory management initiatives and ordering patterns, fluctuating foreign
exchange rates, competitive pressures, and the ability of the Company’s
manufacturing operations and third party manufacturers and logistics providers
and suppliers to meet demand for its products and to avoid inflationary cost
increases and disruption as a result of labor shortages. A discussion of other
factors that could cause results to vary is included in the Company's Annual
Report on Form 10-K for the year ended March 31, 2026 and other periodic reports
filed with the Securities and Exchange Commission.
                                                                                
  About Prestige Consumer Healthcare Inc.                                       
                                                                                
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare
company growing trusted, category-defining brands. Headquartered in New York,
the Company markets, sells, manufactures and distributes its products across the
U.S., Canada, Australia, and select other international markets. Its diverse
portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®,
BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®,
Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little
Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more
at www.prestigeconsumerhealthcare.com.
                                                                                
                       Prestige Consumer Healthcare Inc.                        
                                                                                
      Condensed Consolidated Statements of Income and Comprehensive Income      
                                                                                
                                  (Unaudited)                                   
                                                                                
  (In                                                                           
  thousa…             Three                               Six                   
  except             Months                            Months                   
  per                 Ended                             Ended                   
  share            Septemb…                           Septem…                   
  data)      2026       30,    2025             2026      30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Total      $      336,307    $     274,114    $     602,017    $     523,644  
  Revenu…                                                                       
  Cost of                                                                       
  Sales                                                                         
  Cost of                                                                       
  sales             160,512          120,043          286,978          226,758  
  exclud…                                                                       
  deprec…                                                                       
  Cost of                                                                       
  sales               3,257            2,492            6,313            4,976  
  deprec…                                                                       
  Cost of           163,769          122,535          293,291          231,734  
  sales                                                                         
  Gross             172,538          151,579          308,726          291,910  
  profit                                                                        
  Operat…                                                                       
  Expens…                                                                       
  Advert…                                                                       
  and                52,226           38,701           86,894           73,638  
  market…                                                                       
  General                                                                       
  and                30,893           28,037           74,196           56,493  
  admini…                                                                       
  Deprec…                                                                       
  and                 8,707            5,171           14,404           10,353  
  amorti…                                                                       
  Total                                                                         
  operat…            91,826           71,909          175,494          140,484  
  expens…                                                                       
  Operat…            80,712           79,670          133,232          151,426  
  income                                                                        
  Other                                                                         
  expense                                                                       
  Intere…                                                                       
  expens…            30,026           10,036           43,971           20,239  
  net                                                                           
  Loss on                                                                       
  exting…             1,360                —            1,360                —  
  of debt                                                                       
  Other                                                                         
  expens…             1,876              501            1,910              277  
  net                                                                           
  Total                                                                         
  other              33,262           10,537           47,241           20,516  
  expens…                                                                       
  net                                                                           
  Income                                                                        
  before             47,450           69,133           85,991          130,910  
  income                                                                        
  taxes                                                                         
  Provis…                                                                       
  for                22,155           26,922           31,519           41,233  
  income                                                                        
  taxes                                                                         
  Net        $       25,295    $      42,211    $      54,472    $      89,677  
  income                                                                        
  Earnin…                                                                       
  per                                                                           
  share:                                                                        
  Basic      $         0.53    $        0.86    $        1.15    $        1.82  
  Diluted    $         0.53    $        0.86    $        1.14    $        1.81  
  Weight…                                                                       
  average                                                                       
  shares                                                                        
  outsta…                                                                       
  Basic              47,495           49,025           47,479           49,249  
  Diluted            47,593           49,264           47,599           49,547  
  Compre…                                                                       
  income,                                                                       
  net of                                                                        
  tax:                                                                          
  Curren…                                                                       
  transl…             1,352              655               42            6,059  
  adjust…                                                                       
  Total                                                                         
  other               1,352              655               42            6,059  
  compre…                                                                       
  income                                                                        
  Compre…    $       26,647    $      42,866    $      54,514    $      95,736  
  income                                                                        
                                                                                
                                                                                
                       Prestige Consumer Healthcare Inc.                        
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                                            September 30,                       
                     (In thousands)                  2026       March 31, 2026  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets                                                                
  Cash and cash                      $             46,515    $          63,868  
  equivalents                                                                   
  Accounts                                                                      
  receivable, net                                                               
  of allowance of                                 244,124              191,920  
  $24,135 and                                                                   
  $18,187,                                                                      
  respectively                                                                  
  Inventories                                     179,203              159,132  
  Prepaid expenses                                                              
  and other current                                22,286               16,564  
  assets                                                                        
  Total current                                   492,128              431,484  
  assets                                                                        
  Property, plant                                                               
  and equipment,                                  116,868              121,689  
  net                                                                           
  Operating lease                                                               
  right-of-use                                     24,621               27,780  
  assets                                                                        
  Finance lease                                                                 
  right-of-use                                     20,136               21,776  
  assets, net                                                                   
  Goodwill                                        705,264              581,109  
  Intangible                                    3,357,059            2,299,605  
  assets, net                                                                   
  Other long-term                                   5,585               10,870  
  assets                                                                        
  Total Assets                       $          4,721,661    $       3,494,313  
  Liabilities and                                                               
  Stockholders'                                                                 
  Equity                                                                        
  Current                                                                       
  liabilities                                                                   
  Accounts payable                   $             44,020    $          22,791  
  Accrued interest                                 16,528               15,578  
  payable                                                                       
  Operating lease                                                               
  liabilities,                                      7,218                6,910  
  current                                                                       
  portion                                                                       
  Finance lease                                                                 
  liabilities,                                      2,743                2,656  
  current                                                                       
  portion                                                                       
  Other accrued                                    97,994               72,989  
  liabilities                                                                   
  Total current                                   168,503              120,924  
  liabilities                                                                   
  Long-term debt,                               2,079,324              993,953  
  net                                                                           
  Deferred income                                 489,533              447,417  
  tax liabilities                                                               
  Long-term                                                                     
  operating lease                                                               
  liabilities,                                     17,509               20,955  
  net of current                                                                
  portion                                                                       
  Long-term finance                                                             
  lease                                                                         
  liabilities, net                                 16,576               17,968  
  of current                                                                    
  portion                                                                       
  Other long-term                                   5,551                5,580  
  liabilities                                                                   
  Total Liabilities                             2,776,996            1,606,797  
  Total                                                                         
  Stockholders'                                 1,944,665            1,887,516  
  Equity                                                                        
  Total Liabilities                                                             
  and Stockholders'                  $          4,721,661    $       3,494,313  
  Equity                                                                        
                                                                                
                                                                                
                       Prestige Consumer Healthcare Inc.                        
                                                                                
                                                                                
                Condensed Consolidated Statements of Cash Flows                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                           Six Months Ended                                     
  (In thousands)           September 30,                                        
  Operating Activities     2026                                 2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income               $                          54,472    $       89,677  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                    20,717            15,329  
  amortization                                                                  
  Loss on disposal of                                                           
  property and                                           333               131  
  equipment                                                                     
  Deferred and other                                  15,460            23,211  
  income taxes                                                                  
  Amortization of debt                                 2,109               889  
  origination costs                                                             
  Amortization of                                                               
  acquired inventory                                  17,207                 —  
  step-up                                                                       
  Stock-based                                          5,225             5,449  
  compensation costs                                                            
  Loss on                                                                       
  extinguishment of                                    1,360                 —  
  debt                                                                          
  Non-cash operating                                   4,192             3,879  
  lease cost                                                                    
  Changes in operating                                                          
  assets and                                                                    
  liabilities, net of                                                           
  the effects of                                                                
  acquisitions:                                                                 
                                                                                
  Accounts receivable                                -45,392            -2,580  
  Inventories                                          3,566           -10,277  
  Prepaid expenses and                                                          
  other current                                       -6,181           -11,767  
  assets                                                                        
  Accounts payable                                    16,023            22,545  
  Accrued liabilities                                 24,003             3,923  
  Operating lease                                     -4,185            -3,839  
  liabilities                                                                   
  Other                                                 -256               -71  
  Net cash provided by                                                          
  operating                                          108,653           136,499  
  activities                                                                    
  Investing Activities                                                          
  Purchases of                                                                  
  property, plant and                                 -7,327            -2,940  
  equipment                                                                     
  Acquisitions, net of                            -1,193,557                 —  
  cash acquired                                                                 
  Other                                               -1,757            -1,927  
  Net cash (used in)                              -1,202,641            -4,867  
  investing activities                                                          
  Financing Activities                                                          
  Proceeds from                                    1,140,000                 —  
  issuance of Term Loan                                                         
  Net increase in line                                   887                 —  
  of credit                                                                     
  Term loan repayments                               -30,000                 —  
  Proceeds from                                                                 
  issuance of senior                                 400,000                 —  
  notes                                                                         
  Repayment of senior                               -400,000                 —  
  notes                                                                         
  Payments of debt                                   -28,829                 —  
  issuance costs                                                                
  Payments of finance                                 -1,231            -1,147  
  leases                                                                        
  Proceeds from                                                                 
  exercise of stock                                       94             3,907  
  options                                                                       
  Fair value of shares                                                          
  surrendered as                                      -2,684            -4,216  
  payment of tax                                                                
  withholding                                                                   
  Repurchase of common                                     —          -109,775  
  stock                                                                         
  Other                                               -1,486                 —  
  Net cash provided by                                                          
  (used in) financing                              1,076,751          -111,231  
  activities                                                                    
  Effects of exchange                                                           
  rate changes on cash                                  -116               821  
  and cash equivalents                                                          
  (Decrease) increase                                                           
  in cash and cash                                   -17,353            21,222  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents -                                       63,868            97,884  
  beginning of                                                                  
  period                                                                        
  Cash and cash                                                                 
  equivalents - end of     $                          46,515    $      119,106  
  period                                                                        
  Interest paid            $                          41,124    $       21,879  
  Income taxes paid        $                          24,027    $       25,088  
                                                                                
                                                                                
                       Prestige Consumer Healthcare Inc.                        
                                                                                
                                                                                
                  Condensed Consolidated Statements of Income                   
                                                                                
                                                                                
                               Business Segments                                
                                                                                
                                  (Unaudited)                                   
                                                                                
               Three                                                            
               Months                                                           
               Ended                                                            
               September                                                        
               30, 2026                                                         
 ────────────────────────────────────────────────────────────────────────────── 
               North                  Internati…                                
  (In          American               OTC                   Consolid…           
  thousand…    OTC                    Healthcare                                
               Healthcare                                                       
  Total                                                                         
  segment      $           271,812    $           64,495    $          336,307  
  revenues*                                                                     
  Cost of                  132,992                30,777               163,769  
  sales                                                                         
  Gross                    138,820                33,718               172,538  
  profit                                                                        
  Advertis…                                                                     
  and                       40,488                11,738                52,226  
  marketing                                                                     
  Contribu…    $            98,332    $           21,980    $          120,312  
  margin                                                                        
  Other                                                                         
  operating                                                             39,600  
  expenses                                                                      
  Operating                                                 $           80,712  
  income                                                                        
                                                                                
*Intersegment revenues of $0.9 million were eliminated from the North American
OTC Healthcare segment.
                                                                                
               Six                                                              
               Months                                                           
               Ended                                                            
               September                                                        
               30, 2026                                                         
 ────────────────────────────────────────────────────────────────────────────── 
               North                 Internati…                                 
  (In          American              OTC                    Consolid…           
  thousand…    OTC                   Healthcare                                 
               Healthca…                                                        
  Total                                                                         
  segment      $          498,018    $           103,999    $          602,017  
  revenues*                                                                     
  Cost of                 243,257                 50,034               293,291  
  sales                                                                         
  Gross                   254,761                 53,965               308,726  
  profit                                                                        
  Advertis…                                                                     
  and                      69,418                 17,476                86,894  
  marketing                                                                     
  Contribu…    $          185,343    $            36,489    $          221,832  
  margin                                                                        
  Other                                                                         
  operating                                                             88,600  
  expenses                                                                      
  Operating                                                 $          133,232  
  income                                                                        
                                                                                
*Intersegment revenues of $1.6 million were eliminated from the North American
OTC Healthcare segment.
                                                                                
               Three                                                            
               Months                                                           
               Ended                                                            
               September                                                        
               30, 2025                                                         
 ────────────────────────────────────────────────────────────────────────────── 
               North                  Internati…                                
  (In          American               OTC                   Consolid…           
  thousand…    OTC                    Healthcare                                
               Healthcare                                                       
  Total                                                                         
  segment      $           230,756    $           43,358    $          274,114  
  revenues*                                                                     
  Cost of                  102,348                20,187               122,535  
  sales                                                                         
  Gross                    128,408                23,171               151,579  
  profit                                                                        
  Advertis…                                                                     
  and                       32,033                 6,668                38,701  
  marketing                                                                     
  Contribu…    $            96,375    $           16,503    $          112,878  
  margin                                                                        
  Other                                                                         
  operating                                                             33,208  
  expenses                                                                      
  Operating                                                 $           79,670  
  income                                                                        
                                                                                
*Intersegment revenues of $0.6 million were eliminated from the North American
OTC Healthcare segment.
                                                                                
               Six Months                                                       
               Ended                                                            
               September                                                        
               30, 2025                                                         
 ────────────────────────────────────────────────────────────────────────────── 
               North                  Internati…                                
  (In          American               OTC                   Consolid…           
  thousand…    OTC                    Healthcare                                
               Healthcare                                                       
  Total                                                                         
  segment      $           443,334    $           80,310    $          523,644  
  revenues*                                                                     
  Cost of                  194,526                37,208               231,734  
  sales                                                                         
  Gross                    248,808                43,102               291,910  
  profit                                                                        
  Advertis…                                                                     
  and                       60,987                12,651                73,638  
  marketing                                                                     
  Contribu…    $           187,821    $           30,451    $          218,272  
  margin                                                                        
  Other                                                                         
  operating                                                             66,846  
  expenses                                                                      
  Operating                                                 $          151,426  
  income                                                                        
                                                                                
* Intersegment revenues of $1.2 million were eliminated from the North American
OTC Healthcare segment.
                                                                                
   About Non-GAAP Financial Measures                                            
                                                                                
In addition to financial results reported in accordance with GAAP, we disclose
certain Non-GAAP financial measures ("NGFMs"), including, but not limited to,
Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP
Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP
Adjusted General and Administrative Expense, Non-GAAP Adjusted General and
Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-
GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net
Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP
Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with
GAAP information, in evaluating our operating performance and in making
financial and operational decisions. We believe that the presentation of these
NGFMs provides investors with greater transparency, and provides a more complete
understanding of our business than could be obtained absent these disclosures,
because the supplemental data relating to our financial condition and results of
operations provides additional ways to view our operation when considered with
both our GAAP results and the reconciliations below. In addition, we believe
that the presentation of each of these NGFMs is useful to investors for period-
to-period comparisons of results in assessing shareholder value, and we use
these NGFMs internally to evaluate the performance of our personnel and also to
evaluate our operating performance and compare our performance to that of our
competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a
measure of profitability or liquidity, and may not be directly comparable to
similarly titled NGFMs reported by other companies. These NGFMs have limitations
and they should not be considered in isolation from or as an alternative to
their most closely related GAAP measures reconciled below. Investors should not
rely on any single financial measure when evaluating our business. We recommend
investors review the GAAP financial measures included in this earnings release.
When viewed in conjunction with our GAAP results and the reconciliations below,
we believe these NGFMs provide greater transparency and a more complete
understanding of factors affecting our business than GAAP measures alone.
                                                                                
  NGFMs Defined                                                                 
                                                                                
We define our NGFMs presented herein as follows:

• Non-GAAP Organic Revenues : GAAP Total Revenues excluding revenues associated
with acquisitions and the impact of foreign currency exchange rates in the
periods presented.

• Non-GAAP Organic Revenue Change Percentage : Calculated as the change in Non-
GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic
Revenues.

• Non-GAAP Adjusted Gross Margin : GAAP Gross Profit minus amortization of
inventory fair value step-up, acquired facility remediation, period overhead and
idle capacity costs.

• Non-GAAP Adjusted Gross Margin Percentage : Calculated as Non-GAAP Adjusted
Gross Margin divided by GAAP Total Revenues.

• Non-GAAP Adjusted General and Administrative Expense : GAAP General and
Administrative expenses minus costs associated with acquisitions.

• Non-GAAP Adjusted General and Administrative Expense Percentage : Calculated
as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total
Revenues.

• Non-GAAP EBITDA : GAAP Net Income before interest expense, net, provision for
income taxes, and depreciation and amortization.

• Non-GAAP EBITDA Margin : Calculated as Non-GAAP EBITDA divided by GAAP Total
Revenues.

• Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory
fair value step‑up, acquired facility remediation, period overhead and idle
capacity costs, costs associated with acquisitions, and loss on extinguishment
of debt.

• Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA
divided by GAAP Total Revenues.

• Non-GAAP Adjusted Net Income : GAAP Net Income before amortization of
inventory fair value step-up, depreciation of idle assets during remediation
period, acquired facility remediation, period overhead and idle capacity costs,
costs associated with acquisitions in General and Administrative Expense, loss
on extinguishment of debt, applicable tax impact associated with these items and
normalized tax rate adjustments.

• Non-GAAP Adjusted Diluted EPS : Calculated as Non-GAAP Adjusted Net Income,
divided by the diluted weighted average number of shares outstanding during the
period.

• Non-GAAP Free Cash Flow : Calculated as GAAP Net cash provided by operating
activities less cash paid for capital expenditures.

• Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition and
other costs paid.

• Net Debt : Calculated as total principal amount of debt outstanding
($2,110,000 at September 30, 2026) less cash and cash equivalents ($46,515 at
September 30, 2026). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other
than Net Debt, which is reconciled above) to their most directly comparable
financial measures presented in accordance with GAAP.
Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related
Non-GAAP Organic Revenue Change percentage:
                                                                                
           Three                              Six                               
           Mont…                              Months                            
           Ended                              Ended                             
           Sept…                              Septe…                            
  (In      30,                                30,                               
  thou…    2026                2025           2026                2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Total    $      336,3…       $     274,…    $       602,…       $     523,6…  
  Reve…                                                                         
  Reve…             22.7  %                            15.0  %                  
  Chan…                                                                         
  Adju…                                                                         
  Reve…                                                                         
  asso…                                                                         
  with            -65,0…                 —            -71,…                  —  
  acqu…                                                                         
  (a)                                                                           
  Impa…                                                                         
  of                                                                            
  fore…                —             1,530                —              3,616  
  curr…                                                                         
  exch…                                                                         
  rates                                                                         
  Total           -65,0…             1,530            -71,…              3,616  
  adju…                                                                         
  Non-…                                                                         
  Orga…    $      271,2…       $     275,…    $       530,…       $     527,2…  
  Reve…                                                                         
  Non-…                                                                         
  Orga…             -1.6  %                             0.7  %                  
  Reve…                                                                         
  Chan…                                                                         
                                                                                
(a) Revenues associated with our Breathe Right® portfolio and LaCorium Health
acquisitions are excluded for purposes of calculating Non-GAAP organic revenues.
These revenue adjustments relate to our North America and International OTC
Healthcare segments.
Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and
related Non-GAAP Adjusted Gross Margin percentage:
                                                                                
          Three                                Six                              
          Mont…                                Mon…                             
          Ended                                End…                             
          Sept…                                Sep…                             
  (In     30,                                  30,                              
  tho…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Tot…    $      336,…       $     274,…       $     602,…       $     523…     
  Rev…                                                                          
  GAAP                                                                          
  Gro…    $      172,…       $     151,…       $     308,…       $     291…     
  Pro…                                                                          
  GAAP                                                                          
  Gro…                                                                          
  Pro…                                                                          
  as a                                                                          
  Per…            51.3  %           55.3  %           51.3  %          55.7  %  
  of                                                                            
  GAAP                                                                          
  Tot…                                                                          
  Rev…                                                                          
  Adj…                                                                          
  Amo…                                                                          
  of                                                                            
  inv…           14,3…                 —             17,2…                —     
  fair                                                                          
  val…                                                                          
  ste…                                                                          
  Acq…                                                                          
  fac…                                                                          
  rem…                                                                          
  per…                                                                          
  ove…           7,079                 —             14,2…                —     
  and                                                                           
  idle                                                                          
  cap…                                                                          
  cos…                                                                          
  (a)                                                                           
  Tot…           21,4…                 —             31,4…                —     
  adj…                                                                          
  Non…                                                                          
  Adj…    $      193,…       $     151,…       $     340,…       $     291…     
  Gro…                                                                          
  Mar…                                                                          
  Non…                                                                          
  Adj…                                                                          
  Gro…                                                                          
  Mar…                                                                          
  as a            57.7  %           55.3  %           56.5  %          55.7  %  
  Per…                                                                          
  of                                                                            
  GAAP                                                                          
  Tot…                                                                          
  Rev…                                                                          
                                                                                
(a) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.
Reconciliation of GAAP General and Administrative Expense and related GAAP
General and Administrative Expense percentage to Non-GAAP Adjusted General and
Administrative expense and related Non-GAAP Adjusted General and Administrative
Expense percentage:
                                                                                
          Three                               Six                               
          Mont…                               Mont…                             
          Ended                               Ended                             
          Sept…                               Sept…                             
  (In     30,                                 30,                               
  tho…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Gen…                                                                          
  and     $      30,8…       $     28,…       $      74,…       $     56,4…     
  Adm…                                                                          
  Exp…                                                                          
  GAAP                                                                          
  Gen…                                                                          
  and                                                                           
  Adm…                                                                          
  Exp…                                                                          
  as a             9.2  %          10.2  %           12.3  %           10.8  %  
  Per…                                                                          
  of                                                                            
  GAAP                                                                          
  Tot…                                                                          
  Rev…                                                                          
  Adj…                                                                          
  Cos…                                                                          
  ass…                                                                          
  with             722                —              13,…                 —     
  acq…                                                                          
  (a)                                                                           
  Tot…             722                —              13,…                 —     
  adj…                                                                          
  Non…                                                                          
  Adj…                                                                          
  Gen…    $      30,1…       $     28,…       $      60,…       $     56,4…     
  and                                                                           
  Adm…                                                                          
  Exp…                                                                          
  Non…                                                                          
  Adj…                                                                          
  Gen…                                                                          
  and                                                                           
  Adm…                                                                          
  Exp…                                                                          
  Per…             9.0  %          10.2  %           10.1  %           10.8  %  
  as a                                                                          
  Per…                                                                          
  of                                                                            
  GAAP                                                                          
  Tot…                                                                          
  Rev…                                                                          
                                                                                
(a) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA
Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:
                                                                                
          Three                               Six                               
          Mont…                               Mont…                             
          Ended                               Ended                             
          Sept…                               Sept…                             
  (In     30,                                 30,                               
  tho…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Net     $      25,2…       $     42,…       $      54,…       $     89,6…     
  Inc…                                                                          
  Int…                                                                          
  exp…           30,0…             10,…              43,…             20,2…     
  net                                                                           
  Pro…                                                                          
  for            22,1…             26,…              31,…             41,2…     
  inc…                                                                          
  tax…                                                                          
  Dep…                                                                          
  and            11,9…             7,6…              20,…             15,3…     
  amo…                                                                          
  Non…    $      89,4…       $     86,…       $      150…       $     166,…     
  EBI…                                                                          
  Non…                                                                          
  EBI…            26.6  %          31.7  %           25.0  %           31.8  %  
  Mar…                                                                          
  Adj…                                                                          
  Amo…                                                                          
  of                                                                            
  inv…           14,3…                —              17,…                 —     
  fair                                                                          
  val…                                                                          
  ste…                                                                          
  Acq…                                                                          
  fac…                                                                          
  rem…                                                                          
  per…                                                                          
  ove…           7,079                —              14,…                 —     
  and                                                                           
  idle                                                                          
  cap…                                                                          
  cos…                                                                          
  (a)                                                                           
  Cos…                                                                          
  ass…                                                                          
  with                                                                          
  acq…             722                —              13,…                 —     
  in                                                                            
  G&A                                                                           
  (b)                                                                           
  Loss                                                                          
  on                                                                            
  ext…           1,360                —              1,3…                 —     
  of                                                                            
  debt                                                                          
  Tot…           23,5…                —              46,…                 —     
  adj…                                                                          
  Non…                                                                          
  Adj…    $      112,…       $     86,…       $      197…       $     166,…     
  EBI…                                                                          
  Non…                                                                          
  Adj…            33.6  %          31.7  %           32.7  %           31.8  %  
  EBI…                                                                          
  Mar…                                                                          
                                                                                
(a) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.

(b) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.
Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-
GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per
Share:
                                                                                
  …    T…                                     S…                                
  …    M…                                     M…                                
  …    E…                                     E…                                
  …    S…        2…                  2…       S…       2…                2…     
  …    3…        D…                  D…       3…       D…                D…     
  …    2…        E…        2…        E…       2…       E…       2…       E…     
 ────────────────────────────────────────────────────────────────────────────── 
  …                                                                             
  …                                                                             
  …        2…    $   0…        4…    $   …        …    $   …        …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…        0…         —        —        …        …        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        71         —         —        —        …        —        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…        0…         —        —        …        …        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        7…        0…         —        —        …        …        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…        0…         —        —        …        …        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        -…        -…         —        —        …        …        —        —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        1…        0…        1…        …        …        …        …        …  
  …                                                                             
  …                                                                             
  …        2…        0…        1…        …        …        …        …        …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …    $   5…    $   1…    $   5…    $   …    $   …    $   …    $   …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
                                                                                
(a) Represents depreciation expense recorded during the remediation period
following the acquisition of Pillar5, during which certain production lines were
not operating. Management believes this depreciation is not reflective of
expected ongoing depreciation levels once the facility is fully remediated and
operating at normal production levels.

(b) Represents manufacturing and administrative overhead incurred during a
remediation period following the acquisition of Pillar5, during which production
was significantly constrained. As a result, normal overhead absorption levels
were not achieved, leading to elevated unit costs. Management believes these
costs are not indicative of the Company’s expected ongoing operating cost
structure once the facility is fully remediated and operating at normal
production levels.

(c) Costs related to the consummation of the acquisition process such as legal
and other acquisition-related professional fees.

(d) The income tax adjustments are determined using applicable rates in the
taxing jurisdictions in which the above adjustments relate and includes both
current and deferred income tax expense (benefit) based on the specific nature
of specific Non-GAAP performance measure.

(e) Income tax adjustments to adjust for discrete income tax items.

Note: Amounts may not add due to rounding.
Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP
Adjusted Free Cash Flow:
                                                                                
           Three                               Six                              
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
  (In      30,                                 30,                              
  thou…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Net      $        25,295    $      42,211    $        54,472    $     89,677  
  Inco…                                                                         
  Adju…                                                                         
  Adju…                                                                         
  to                                                                            
  reco…                                                                         
  net                                                                           
  inco…                                                                         
  to                                                                            
  net                                                                           
  cash                                                                          
  prov…                                                                         
  by                48,077           29,324             66,603          48,888  
  oper…                                                                         
  acti…                                                                         
  as                                                                            
  shown                                                                         
  in                                                                            
  the                                                                           
  Stat…                                                                         
  of                                                                            
  Cash                                                                          
  Flows                                                                         
  Chan…                                                                         
  in                                                                            
  oper…                                                                         
  asse…                                                                         
  and                                                                           
  liab…                                                                         
  net                                                                           
  of                                                                            
  effe…                                                                         
  of                -35,5…          -14,049            -12,422          -2,066  
  acqu…                                                                         
  as                                                                            
  shown                                                                         
  in                                                                            
  the                                                                           
  Stat…                                                                         
  of                                                                            
  Cash                                                                          
  Flows                                                                         
  Total             12,570           15,275             54,181          46,822  
  adju…                                                                         
  GAAP                                                                          
  Net                                                                           
  cash                                                                          
  prov…             37,865           57,486            108,653          136,4…  
  by                                                                            
  oper…                                                                         
  acti…                                                                         
  Purc…                                                                         
  of                                                                            
  prop…             -3,624           -2,102             -7,327          -2,940  
  and                                                                           
  equi…                                                                         
  Non-…                                                                         
  Free              34,241           55,384            101,326          133,5…  
  Cash                                                                          
  Flow                                                                          
  Acqu…                                                                         
  and                                                                           
  other              5,000                —             21,664               —  
  costs                                                                         
  paid                                                                          
  Non-…                                                                         
  Adju…                                                                         
  Free     $        39,241    $      55,384    $       122,990    $     133,5…  
  Cash                                                                          
  Flow                                                                          
                                                                                
                                                                                
  Outlook for Fiscal Year 2027                                                  
                                                                                
:
Reconciliation of Projected GAAP Net cash provided by operating activities to
Projected Non-GAAP Free Cash Flow

and Projected Non-GAAP Adjusted Free Cash Flow:
                                                              
  (In millions)                                               
 ──────────────────────────────────────────────────────────── 
  Projected FY'27 GAAP Net cash provided by           $  269  
  operating activities                                        
  Additions to property and equipment for cash           -26  
  Projected FY'27 Non-GAAP Free Cash Flow                243  
  Acquisition and other costs paid                        22  
  Projected FY'27 Non-GAAP Adjusted Free Cash Flow    $  265  
                                                              
Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted
Diluted EPS (a):
                                                                                
                                         Low                 High               
 ────────────────────────────────────────────────────────────────────────────── 
  Projected FY'27 GAAP Diluted EPS       $     3.53          $      3.60        
  Adjustments:                                                                  
  Costs associated with Pillar5                                                 
  manufacturing optimization and                     0.30                 0.30  
  integration                                                                   
  Costs associated with acquisitions                                            
  of                                           0.64                 0.64        
  the Breathe Right® portfolio and                                              
  LaCorium Health                                                               
  Loss on extinguishment of debt               0.03                 0.03        
  Tax impact of adjustments and                                                 
  normalized                                  -0.02                -0.02        
  tax rate adjustments                                                          
  Total adjustments                      $     0.95          $      0.95        
  Projected FY'27 Non-GAAP Adjusted      $     4.48          $      4.55        
  Diluted EPS                                                                   
                                                                                
(a) The above reconciliation of this forward-looking non-GAAP financial measure
only includes adjustments for Q1 and Q2 2027 and does not include additional
adjustments for the remainder of fiscal 2027. These future adjustments are
highly uncertain, given the significant variability and difficulty in making
accurate projections of the adjustments related to the Breathe Right® portfolio
and LaCorium Health acquisitions and the costs associated with Pillar5
manufacturing optimization and integration. As a result, the Company is unable
to quantify those future adjustments, which are likely significant, without
unreasonable efforts.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PBH/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.